P1-132: Phase II study of erlotinib plus bevacizumab in patients with previously treated malignant pleural mesothelioma  by Jackman, David M. et al.
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS602
reviewed and the immunohistochemical analyses were conducted, the 
diagnosis of mesothelioma was determined by the discussion with the 
clinical and radiological informations. The diagnostic categories of 
each case are as follows; undetermined, category 1 (deﬁnitely not), 
category 2 (unlikely), category 3 (possibly), category 4 (probably) and 
category 5 (Deﬁnite).
Results and Discussion: 1) The ratio of each diagnostic category 
is as follows; “undetermined”, 12 cases (6%), category 1, 22 cases 
(11%), category 2, 5 cases (2%), category 3, 17 cases (8%), category 
4, 33 cases (16%), category 5, 115 cases (57%). 2) Category 1 or 2 
cases included 8 lung cancers, 6 pleuritis, 1 malignant lymphoma, and 
1 solitary ﬁbrous tumor in male, 1 lung cancer, 6 adenocarcinomas 
involving peritoneum, 1 malignant lymphoma, 1 rhabdomyosarcoma 
and 2 pleuritis in female. 3) The frequency of higher category cases 
in “pleural origin” cases tended to be higher than that in “peritoneal ori-
gin” cases. 4) The ratio of category 5 was 59% in male cases, and 43% 
in female cases. 5) The ratio of sarcomatoid type was 33% in category 
4, and 16% in category 5. These results indicated that approximately 
15% cases died of “mesothelioma” in Japan contained diagnostically 
suspicious cases. Peritoneal cases, female cases and sarcomatoid type 
cases seems to be especially difﬁcult to diagnose accurately.
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Background: The treatment strategy for thymoma with pleural dis-
semination remains controversial. Although multimodality therapy 
may improve their survival, it has not been concluded what regimen 
of chemotherapy is optimal or what type of operation should be done. 
We reviewed our experience with a multidisciplinary approach and 
evaluated the usefulness of extrapleural pneumonectomy (EPP) in the 
treatment of disseminated thymoma.
Patients and Methods: From 1988 to 2003, eleven patients, including 
two recurrent patients, were treated for invasive thymoma with pleural 
dissemination.
Our multimodality therapy consisted of chemotherapy, surgery, and/or 
radiotherapy. The chemotherapy regimen consisted of cisplatin (20 
mg/m2/day continuous infusion on days 1 through 4), doxorubicin (40 
mg/m2 intravenously on day 1), and methylprednisolone (1,000 mg/day 
intravenously on days 1 through 4 and 500 mg/day intravenously on 
days 5 and 6) (CAMP). Thymomectomy with resection of the visible 
dissemination (usual operation) was principally performed and EPP 
was carried out only for chemoresistant thymoma or for recurrent dis-
semination after usual operation. Radiation therapy was administered 
to the mediastinal or residual tumor areas at the total dose of more than 
50 Gy.
Result: The response rate of CAMP regimen was 100%.Usual opera-
tion was accomplished in 4 patients, EPP in 3 patients. There was no 
operative death. The 5-year and 10-year overall survivals of all patients 
were both 72.7 %. Disease free 5-year and 10-year survivals were 25.0 
% for usual operation cases and 66.7 % for EPP cases. 
Conclusions: We concider that this multidisciplinary treatment is a 
justiﬁable initial treatment for patients with disseminated thymoma. 
Furthermore, for achieving cure or maintaining good quality of life, 
EPP could be one of the surgical treatment of choice for thymoma 
patient with pleural dissemination, especially for chemoresistant or 
recurrent disseminated thymoma. 
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Mediastinal liposarcomas are mesenchymal tumours arising from 
adipose tissue. They are very rare and the most frequent compartment 
is posterior mediastinum. They have a great tendency to local inva-
sion. Most of the cases are symptomatic and these symptoms are due 
to local effects. Although they can reach to big sizes, distant metastasis 
rates are low for liposarcomas. In half of the patients, local relapses are 
developing after resection. A mediastinal liposarcoma case is aimed to 
be presented in this study since it is very rare. 
A 42 year-old male patient with cough and dyspnea complaints had 
mediastinal giant mass excision history by 2 right thoracotomy and 
one left thoracotomy 12 years ago. In radiological examination, a giant 
mass of lipoid density, which is extending from thoracic inlet to dia-
phragm level, ﬁlling in posterior mediastinum, pressing environmental 
structures has been determined. This patient did not have pathology 
concerning with other organ systems and he was applied right thoracot-
omy in our clinic. Giant mass lesion (approximately 30 cm diameter) 
covering right hemithorax and mediastinum was completely resected. 
There was not any postoperative complication and it was reported as 
“well-differentiated liposarcoma” pathologically. After 3 years from 
surgical operation, a mass in mediastinum surrounding oesophagus was 
determined in thorax CT. He was applied right thoracotomy and mass, 
with sizes 7X6X6 cm, was completely resected. It was diagnosed as 
liposarcoma by pathology report. This patient was taken into follow up 
program in our clinical. 
We suggest that complete surgical excision is the primary therapy, and 
when impossible subtotal resection with adjuvant chemotherapy or 
radiotherapy for mediastinal liposarcoma should be performed.
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